{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:32:09Z","timestamp":1782567129888,"version":"3.54.5"},"reference-count":201,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Two decades after reports of the anti-pruritic effects of botulinum neurotoxins (BoNTs), there is still no approved product for the anti-itch indication of BoNTs, and most clinical case reports still focus on the off-label use of BoNTs for various itchy conditions. Few randomized clinical trials have been conducted with controversial results, and the beneficial effects of BoNTs against itch are mainly based on case studies and case series. These studies are valuable in presenting the potential application of BoNTs in chronic pruritic conditions, but due to the nature of these studies, they are categorized as providing lower levels of evidence or lower grades of recommendation. To obtain approval for the anti-pruritic indication of BoNTs, higher levels of evidence are required, which can be achieved through conducting large-scale and well-designed studies with proper control groups and established careful and reliable primary and secondary outcomes. In addition to clinical evidence, presenting the mechanism-based antipruritic action of BoNTs can potentially strengthen, accelerate, and facilitate the current efforts towards further investments in accelerating the field towards the potential approval of BoNTs for itchy conditions. This review, therefore, aimed to provide the state-of-the-art mechanisms underlying the anti-itch effect of BoNTs from basic studies that resemble various clinical conditions with itch as a hallmark. Evidence of the neuronal, glial, and immune modulatory actions of BoNTs in reducing the transmission of itch are presented, and future potential directions are outlined.<\/jats:p>","DOI":"10.3390\/toxins14100701","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T22:45:29Z","timestamp":1665614729000},"page":"701","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["How Does Botulinum Toxin Inhibit Itch?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0109-3600","authenticated-orcid":false,"given":"Parisa","family":"Gazerani","sequence":"first","affiliation":[{"name":"Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University, 0130 Oslo, Norway"},{"name":"Department of Health Science and Technology, Faculty of Medicine, Aalborg University, 9220 Aalborg East, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.20003","article-title":"Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin","volume":"19","author":"Erbguth","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/archneur.1963.00460120102011","article-title":"Botulism","volume":"9","author":"Tyler","year":"1963","journal-title":"Arch. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000317517","article-title":"The Unusual History and the Urological Applications of Botulinum Neurotoxin","volume":"85","author":"Hanchanale","year":"2010","journal-title":"Urol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7002a1","article-title":"Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021","volume":"70","author":"Rao","year":"2021","journal-title":"MMWR Recomm. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","article-title":"From poison to remedy: The chequered history of botulinum toxin","volume":"115","author":"Erbguth","year":"2008","journal-title":"J. Neural Transm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e01469-18","DOI":"10.1128\/mBio.01469-18","article-title":"Botulinum Neurotoxin-Producing Bacteria. Isn\u2019t It Time that We Called a Species a Species?","volume":"9","author":"Smith","year":"2018","journal-title":"mBio"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5334\/tohm.321","article-title":"History of Botulinum Toxin Treatment in Movement Disorders","volume":"6","author":"Jabbari","year":"2016","journal-title":"Tremor Other Hyperkinetic Mov."},{"key":"ref_8","first-page":"489","article-title":"Botulinum toxin: Bioweapon & magic drug","volume":"132","author":"Dhaked","year":"2010","journal-title":"Indian J. Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/milmed\/usx047","article-title":"Yesterday and Today: The Impact of Research Conducted at Camp Detrick on Botulinum Toxin","volume":"183","author":"Lebeda","year":"2018","journal-title":"Mil. Med."},{"key":"ref_10","unstructured":"Holst, O. (2000). Purification of Clostridium botulinum Type A Neurotoxin. Bacterial Toxins: Methods and Protocols, Humana Press."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","article-title":"The action of botulinum toxin on the neuro-muscular junction","volume":"109","author":"Burgen","year":"1949","journal-title":"J. Physiol."},{"key":"ref_12","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus","volume":"79","author":"Scott","year":"1981","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/toxins4100913","article-title":"Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments","volume":"4","author":"Chen","year":"2012","journal-title":"Toxins"},{"key":"ref_14","first-page":"123","article-title":"Clinical use of botulinum neurotoxins","volume":"195","author":"Cardoso","year":"1995","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cps.2011.03.010","article-title":"An overview of botulinum toxins: Past, present, and future","volume":"38","author":"Cartee","year":"2011","journal-title":"Clin. Plast. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2146\/ajhp050137","article-title":"Unlabeled uses of botulinum toxins: A review, part 1","volume":"63","author":"Cheng","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2146\/sp\/06001","article-title":"Unlabeled uses of botulinum toxins: A review, part 2","volume":"63","author":"Cheng","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum Toxin: Mechanisms of Action","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00204-022-03271-9","article-title":"Toxicology and pharmacology of botulinum and tetanus neurotoxins: An update","volume":"96","author":"Pirazzini","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Peck, M.W., Smith, T.J., Anniballi, F., Austin, J.W., Bano, L., Bradshaw, M., Cuervo, P., Cheng, L.W., Derman, Y., and Dorner, B.G. (2017). Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature. Toxins, 9.","DOI":"10.3390\/toxins9010038"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1024907920934901","article-title":"A review on iatrogenic botulism","volume":"27","author":"Fung","year":"2020","journal-title":"Hong Kong J. Emerg. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ccc.2005.06.008","article-title":"Botulinum toxin","volume":"21","author":"Horowitz","year":"2005","journal-title":"Crit. Care Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e4228","DOI":"10.1097\/GOX.0000000000004228","article-title":"The Multispecialty Toxin: A Literature Review of Botulinum Toxin","volume":"10","author":"Bach","year":"2022","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jabbari, B. (2020). Botulinum Toxin Treatment in Veterinary Medicine: Clinical Implications. Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine, Springer International Publishing.","DOI":"10.1007\/978-3-030-50691-9"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5603\/PJNNS.a2021.0028","article-title":"Botulinum toxin type-A preparations are not the same medications\u2014Clinical studies (Part 2)","volume":"55","author":"Bogucki","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5603\/PJNNS.a2021.0027","article-title":"Botulinum toxin type-A preparations are not the same medications\u2014Basic science (Part 1)","volume":"55","author":"Car","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_29","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: A review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/09638280701568296","article-title":"Pharmacology of therapeutic botulinum toxin preparations","volume":"29","author":"Dressler","year":"2007","journal-title":"Disabil. Rehabil."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Choudhury, S., Baker, M.R., Chatterjee, S., and Kumar, H. (2021). Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins, 13.","DOI":"10.3390\/toxins13010058"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Spiegel, L.L., Ostrem, J.L., and Bledsoe, I.O. (2020). FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins, 12.","DOI":"10.3390\/toxins12050332"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40257-020-00532-0","article-title":"Alternative Clinical Indications of Botulinum Toxin","volume":"21","author":"Alster","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lewandowski, M., \u015awierczewska, Z., and Bara\u0144ska-Rybak, W. (2022). Off-Label Use of Botulinum Toxin in Dermatology\u2014Current State of the Art. Molecules, 27.","DOI":"10.3390\/molecules27103143"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e15205","DOI":"10.1111\/dth.15205","article-title":"Emerging off-label esthetic uses of botulinum toxin in dermatology","volume":"35","author":"Phan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14737175.2021.1958677","article-title":"Beyond chronic migraine: A systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders","volume":"21","author":"Argyriou","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jpsychires.2021.01.016","article-title":"Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis","volume":"135","author":"Schulze","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e070721194556","DOI":"10.2174\/1573399817666210707112413","article-title":"The Treatment of Painful Diabetic Neuropathy","volume":"18","author":"Sloan","year":"2022","journal-title":"Curr. Diabetes Rev."},{"key":"ref_39","first-page":"e26856","article-title":"Therapeutic Efficacy of Botulinum Toxin in Trigeminal Neuralgia","volume":"14","author":"Kayani","year":"2022","journal-title":"Cureus"},{"key":"ref_40","first-page":"12","article-title":"Evaluation of Botulinum Toxin Type A Injection in the Treatment of Localized Chronic Pruritus","volume":"13","author":"Gharib","year":"2020","journal-title":"J. Clin. Aesthet Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1468-3083.2007.02457.x","article-title":"Botulinum toxin type-A for the treatment of inverse psoriasis","volume":"22","author":"Zanchi","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/archderm.143.8.980","article-title":"Successful treatment of notalgia paresthetica with botulinum toxin type A","volume":"143","author":"Weinfeld","year":"2007","journal-title":"Arch. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gazerani, P. (2018). Antipruritic Effects of Botulinum Neurotoxins. Toxins, 10.","DOI":"10.3390\/toxins10040143"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10354-017-0553-7","article-title":"The history of Botulinum toxin: From poison to beauty","volume":"167","author":"Kumar","year":"2017","journal-title":"Wien. Med. Wochenschr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2147\/CCID.S332247","article-title":"Utilities of Botulinum Toxins in Dermatology and Cosmetology","volume":"14","author":"Naik","year":"2021","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrn1950","article-title":"The neurobiology of itch","volume":"7","author":"Ikoma","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron\u2013expressed IL-31 receptor mediates T helper cell\u2013dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dth.12025","article-title":"Understanding the pathophysiology of itch","volume":"26","author":"Garibyan","year":"2013","journal-title":"Dermatol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/JD9.0000000000000045","article-title":"Sensitization Mechanisms of Chronic Itch","volume":"2","author":"Jin","year":"2019","journal-title":"Int. J. Dermatol. Venereol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","article-title":"Peripheral itch sensitization in atopic dermatitis","volume":"71","author":"Tominaga","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"644760","DOI":"10.3389\/fmed.2021.644760","article-title":"Itch in Atopic Dermatitis\u2014What Is New?","volume":"8","author":"Legat","year":"2021","journal-title":"Front. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neuron.2018.03.023","article-title":"Peripheral and Central Mechanisms of Itch","volume":"98","author":"Dong","year":"2018","journal-title":"Neuron"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"745658","DOI":"10.3389\/fphar.2022.745658","article-title":"Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk","volume":"13","author":"Lisztes","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"803752","DOI":"10.1155\/2015\/803752","article-title":"Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities","volume":"2015","author":"Tarikci","year":"2015","journal-title":"Sci. World J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MNH.0000000000000824","article-title":"Pruritus in chronic kidney disease","volume":"31","author":"Uppal","year":"2022","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jceh.2021.12.013","article-title":"Skin Changes in Cirrhosis","volume":"12","author":"Bhandari","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102573","DOI":"10.1016\/j.conb.2022.102573","article-title":"Mechanisms and therapeutic targets for neuropathic itch","volume":"75","author":"Pereira","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1067\/mjd.2002.120455","article-title":"Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study","volume":"46","author":"Heckmann","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1067\/mjd.2002.124605","article-title":"Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin","volume":"47","author":"Swartling","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Martina, E., Diotallevi, F., Radi, G., Campanati, A., and Offidani, A. (2021). Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins, 13.","DOI":"10.3390\/toxins13020120"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13023-021-01710-x","article-title":"Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: An open-label 6-month pilot interventional study","volume":"16","author":"Dreyfus","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_62","first-page":"e14319","article-title":"Breaking paradigms in the treatment of psoriasis: Use of botulinum toxin for the treatment of plaque psoriasis","volume":"33","author":"Franco","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000452341","article-title":"Botulinum Toxin Off-Label Use in Dermatology: A Review","volume":"3","author":"Campanati","year":"2017","journal-title":"Ski. Appendage Disord."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kim, Y.S., Hong, E.S., and Kim, H.S. (2017). Botulinum Toxin in the Field of Dermatology: Novel Indications. Toxins, 9.","DOI":"10.3390\/toxins9120403"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jaad.2013.12.006","article-title":"Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial","volume":"70","author":"Maari","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaad.2017.08.001","article-title":"Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus","volume":"78","author":"Boozalis","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.burns.2012.05.014","article-title":"The use of botulinum toxin in the management of burns itching: Preliminary results","volume":"38","author":"Akhtar","year":"2012","journal-title":"Burns"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ad.2013.09.003","article-title":"Notalgia paresthetica: Treatment using intradermal botulinum toxin A","volume":"105","author":"Allegue","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2010.09783.x","article-title":"Botulinum toxin type A for neuropathic itch","volume":"163","author":"Wallengren","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2133.2011.10749.x","article-title":"Botulinum A toxin and brachioradial pruritus","volume":"166","author":"Kavanagh","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/WNF.0b013e3181672225","article-title":"Relief of intractable pruritus after administration of botulinum toxin A (botox): A case report","volume":"31","author":"Salardini","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2230.2011.04329.x","article-title":"Pruritic axillary papules","volume":"37","author":"Rai","year":"2012","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archdermatol.2011.111","article-title":"Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A","volume":"147","author":"Saber","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_75","first-page":"68","article-title":"Successful botulinum toxin (onabotulinumtoxinA) treatment of Hailey-Hailey disease","volume":"14","author":"Ho","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Toyama, S., Tominaga, M., and Takamori, K. (2022). Treatment Options for Troublesome Itch. Pharmaceuticals, 15.","DOI":"10.3390\/ph15081022"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/pde.14552","article-title":"Treatment of pruritus with botulinum toxin in a pediatric patient with Fox-Fordyce disease","volume":"38","author":"Klager","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_78","first-page":"2059513120926628","article-title":"The use of botulinum toxin in keloid scar management: A literature review","volume":"6","author":"Sohrabi","year":"2020","journal-title":"Scars Burn Heal."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"NP1721","DOI":"10.1093\/asj\/sjab105","article-title":"Synergic Effect of Botulinum Toxin Type A and Triamcinolone Alleviates Scar Pruritus by Modulating Epidermal Hyperinnervation: A Preliminary Report","volume":"41","author":"Huang","year":"2021","journal-title":"Aesthet. Surg. J."},{"key":"ref_80","first-page":"32","article-title":"Evaluation of Botulinum Toxin A as an Optional Treatment for Atopic Dermatitis","volume":"13","author":"Khattab","year":"2020","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: A review from the patient\u2019s perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis","volume":"29","author":"Fabbri","year":"2016","journal-title":"Neurotox. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-2133.2009.09305.x","article-title":"Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin","volume":"161","author":"Gazerani","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0928-4257(01)00086-9","article-title":"Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission","volume":"96","author":"Meunier","year":"2002","journal-title":"J. Physiol. Paris"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0072-9752(07)01511-4","article-title":"Chapter 11 Botulism","volume":"Volume 91","author":"Johnson","year":"2008","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0733-8635(03)00019-6","article-title":"Development of botulinum toxin therapy","volume":"22","author":"Scott","year":"2004","journal-title":"Dermatol. Clin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40272-019-00344-8","article-title":"Botulinum Toxin in the Management of Children with Cerebral Palsy","volume":"21","author":"Multani","year":"2019","journal-title":"Pediatric Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: Genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gardner, A.P., and Barbieri, J.T. (2018). Light Chain Diversity among the Botulinum Neurotoxins. Toxins, 10.","DOI":"10.3390\/toxins10070268"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1567-424X(09)70353-8","article-title":"Chapter 17 Botulinum toxin mechanisms of action","volume":"Volume 57","author":"Hallett","year":"2004","journal-title":"Supplements to Clinical Neurophysiology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0035-1571215","article-title":"The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems","volume":"36","author":"Kumar","year":"2016","journal-title":"Semin. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Matak, I., B\u00f6lcskei, K., Bach-Rojecky, L., and Helyes, Z. (2019). Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 11.","DOI":"10.3390\/toxins11080459"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10787-010-0069-x","article-title":"The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: A systematic review and meta analysis","volume":"19","author":"Zhang","year":"2011","journal-title":"Inflammopharmacology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1177\/0022034519875053","article-title":"Botulinum Toxin Type A in Dental Medicine","volume":"98","author":"Jabbari","year":"2019","journal-title":"J. Dent. Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Lippi, L., de Sire, A., Folli, A., D\u2019Abrosca, F., Grana, E., Baricich, A., Carda, S., and Invernizzi, M. (2022). Multidimensional Effectiveness of Botulinum Toxin in Neuropathic Pain: A Systematic Review of Randomized Clinical Trials. Toxins, 14.","DOI":"10.3390\/toxins14050308"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3284446","DOI":"10.1155\/2022\/3284446","article-title":"Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review","volume":"2022","author":"Shaterian","year":"2022","journal-title":"Pain Res. Manag."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","article-title":"OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/toxins7093818","article-title":"Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders","volume":"7","author":"Luvisetto","year":"2015","journal-title":"Toxins"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1111\/bph.12763","article-title":"Therapeutic use of botulinum toxin in migraine: Mechanisms of action","volume":"171","author":"Ramachandran","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ane.12906","article-title":"Botulinum toxin: A review of the mode of action in migraine","volume":"137","author":"Do","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.toxicon.2020.02.017","article-title":"Chronic migraine and Botulinum Toxin Type A: Where do paths cross?","volume":"178","author":"Martinelli","year":"2020","journal-title":"Toxicon"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2217\/pmt.14.30","article-title":"Botulinum neurotoxin A for chronic migraine headaches: Does it work and how?","volume":"4","author":"Cairns","year":"2014","journal-title":"Pain Manag."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"Ns20180058","DOI":"10.1042\/NS20180058","article-title":"Therapeutic use of botulinum toxin in pain treatment","volume":"2","author":"Kumar","year":"2018","journal-title":"Neuronal Signal."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache J. Head Face Pain"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00424-013-1284-2","article-title":"New insights into the mechanisms of itch: Are pain and itch controlled by distinct mechanisms?","volume":"465","author":"Liu","year":"2013","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tins.2010.09.002","article-title":"The multiple pathways for itch and their interactions with pain","volume":"33","author":"Davidson","year":"2010","journal-title":"Trends Neurosci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.neuron.2020.03.021","article-title":"Differential Coding of Itch and Pain by a Subpopulation of Primary Afferent Neurons","volume":"106","author":"Sharif","year":"2020","journal-title":"Neuron"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ijd.14678","article-title":"Pain and Pruritus: A study of their similarities and differences","volume":"59","author":"Anzelc","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.pain.2010.07.029","article-title":"Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis","volume":"151","author":"Gazerani","year":"2010","journal-title":"Pain"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","article-title":"Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin","volume":"141","author":"Gazerani","year":"2009","journal-title":"Pain"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pain.2006.04.014","article-title":"The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization","volume":"122","author":"Gazerani","year":"2006","journal-title":"Pain"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/toxins6020592","article-title":"Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles","volume":"6","author":"Kulas","year":"2014","journal-title":"Toxins"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jcmm.12562","article-title":"Botulinum neurotoxin type A modulates vesicular release of glutamate from satellite glial cells","volume":"19","author":"Poulsen","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1155\/2014\/410415","article-title":"Blockade of glutamate release by botulinum neurotoxin type A in humans: A dermal microdialysis study","volume":"19","author":"Karshenas","year":"2014","journal-title":"Pain Res. Manag."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache J. Head Face Pain"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(00)00260-4","article-title":"Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms","volume":"59","author":"Purkiss","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.toxicon.2017.02.010","article-title":"Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats","volume":"129","author":"Lora","year":"2017","journal-title":"Toxicon"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin A reduces formalin-induced pain","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0333102416636843","article-title":"Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors\u2019 responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?","volume":"36","author":"Zhang","year":"2016","journal-title":"Cephalalgia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/brain\/awab461","article-title":"OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients","volume":"145","author":"Gfrerer","year":"2022","journal-title":"Brain"},{"key":"ref_121","first-page":"1463","article-title":"Neurophysiology of pruritus: Cutaneous elicitation of itch","volume":"139","author":"Steinhoff","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.neuron.2021.07.020","article-title":"Dissecting the precise nature of itch-evoked scratching","volume":"109","author":"Wimalasena","year":"2021","journal-title":"Neuron"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9625936","DOI":"10.1155\/2018\/9625936","article-title":"Pruritus: Progress toward Pathogenesis and Treatment","volume":"2018","author":"Song","year":"2018","journal-title":"Biomed Res. Int."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neubiorev.2018.01.009","article-title":"The vicious cycle of itch and anxiety","volume":"87","author":"Sanders","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5483\/BMBRep.2016.49.9.108","article-title":"The peripheral and central mechanisms underlying itch","volume":"49","author":"Lee","year":"2016","journal-title":"BMB Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.neuroimage.2011.10.099","article-title":"A tale of two itches. Common features and notable differences in brain activation evoked by cowhage and histamine induced itch","volume":"59","author":"Papoiu","year":"2012","journal-title":"Neuroimage"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-biophys-051013-022826","article-title":"Itch mechanisms and circuits","volume":"43","author":"Han","year":"2014","journal-title":"Annu. Rev. Biophys."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00281-015-0530-4","article-title":"Trp channels and itch","volume":"38","author":"Sun","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2021.10.024","article-title":"Peripheral Mechanisms of Itch","volume":"142","author":"Guo","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2021.07.078","article-title":"Itch: Pathogenesis and treatment","volume":"86","author":"Sutaria","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: From mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/exd.13078","article-title":"Preclinical and human surrogate models of itch","volume":"25","author":"Hoeck","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4274\/imj.galenos.2018.32068","article-title":"Factors Affecting the Etiology of Intractable Pruritus in Hospitalized Patients without Primary Skin Lesions","volume":"20","author":"Akdogan","year":"2019","journal-title":"\u0130stanbul Med. J"},{"key":"ref_134","first-page":"587","article-title":"Human experimental pain models: A review of standardized methods in drug development","volume":"17","author":"Reddy","year":"2012","journal-title":"J. Res. Med. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/ejp.1768","article-title":"Human surrogate models of central sensitization: A critical review and practical guide","volume":"25","author":"Quesada","year":"2021","journal-title":"Eur. J. Pain"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.brainresrev.2008.12.016","article-title":"Predicting therapeutic efficacy\u2014Experimental pain in human subjects","volume":"60","author":"Chizh","year":"2009","journal-title":"Brain Res. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1213\/01.ane.0000194447.46763.73","article-title":"A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model","volume":"102","author":"Sycha","year":"2006","journal-title":"Anesth. Analg."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-94-017-7537-3_1","article-title":"Assessment of Itch and Pain in Animal Models and Human Subjects","volume":"904","author":"Yuan","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdermsci.2015.06.004","article-title":"Experimental elicitation of itch: Evoking and evaluation techniques","volume":"80","author":"Fostini","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pain.2004.10.003","article-title":"Electrically evoked itch in humans","volume":"113","author":"Ikoma","year":"2005","journal-title":"Pain"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.pain.2013.02.021","article-title":"Mechanically evoked itch in humans","volume":"154","author":"Fukuoka","year":"2013","journal-title":"Pain"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/08990229109144750","article-title":"Psychophysical studies of the itch sensation and itchy skin (\u201calloknesis\u201d) produced by intracutaneous injection of histamine","volume":"8","author":"Simone","year":"1991","journal-title":"Somatosens. Mot. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/07367228709144620","article-title":"The magnitude and duration of itch produced by intracutaneous injections of histamine","volume":"5","author":"Simone","year":"1987","journal-title":"Somatosens. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1152\/jn.91268.2008","article-title":"Pruritic and nociceptive sensations and dysesthesias from a spicule of cowhage","volume":"101","author":"LaMotte","year":"2009","journal-title":"J. Neurophysiol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Papoiu, A.D., Tey, H.L., Coghill, R.C., Wang, H., and Yosipovitch, G. (2011). Cowhage-induced itch as an experimental model for pruritus. A comparative study with histamine-induced itch. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017786"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pain.2009.03.001","article-title":"Similar itch and nociceptive sensations evoked by punctate cutaneous application of capsaicin, histamine and cowhage","volume":"144","author":"Sikand","year":"2009","journal-title":"Pain"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1523\/JNEUROSCI.1192-11.2011","article-title":"BAM8-22 peptide produces itch and nociceptive sensations in humans independent of histamine release","volume":"31","author":"Sikand","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"14532","DOI":"10.1523\/JNEUROSCI.3509-12.2012","article-title":"Mechanisms of itch evoked by \u03b2-alanine","volume":"32","author":"Liu","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s000110050213","article-title":"Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch?","volume":"46","author":"Weisshaar","year":"1997","journal-title":"Inflamm. Res."},{"key":"ref_150","first-page":"1021","article-title":"Prolonged antipruritic effect of botulinum toxin type A on cowhage-induced itch","volume":"Volume 97","author":"Nattkemper","year":"2017","journal-title":"ACTA DERMATO-VENEREOLOGICA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/jid.1955.138","article-title":"The role of proteolytic enzymes in the production of pruritus in man","volume":"25","author":"Arthur","year":"1955","journal-title":"J. Investig. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1152\/physrev.00017.2019","article-title":"Physiology and Pathophysiology of Itch","volume":"100","author":"Cevikbas","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2340\/00015555-1878","article-title":"Microdialysis of inflammatory mediators in the skin: A review","volume":"94","author":"Hersini","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"FSO63","DOI":"10.4155\/fso.15.63","article-title":"Animal models are essential to biological research: Issues and perspectives","volume":"1","author":"Montagutelli","year":"2015","journal-title":"Future Sci. OA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0394632016671728","article-title":"Critical evaluation of challenges and future use of animals in experimentation for biomedical research","volume":"29","author":"Singh","year":"2016","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Kahremany, S., Hofmann, L., Gruzman, A., and Cohen, G. (2020). Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144883"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2133.1963.tb13948.x","article-title":"An experimental method for screening antipruritic agents","volume":"75","author":"Joglekar","year":"1963","journal-title":"Br. J. Dermatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0160-5402(83)90073-6","article-title":"An animal model for preclinical screening of systemic antipruritic agents","volume":"10","author":"Gmerek","year":"1983","journal-title":"J. Pharmacol. Methods"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00000542-200003000-00023","article-title":"An experimental itch model in monkeys: Characterization of intrathecal morphine-induced scratching and antinociception","volume":"92","author":"Ko","year":"2000","journal-title":"Anesthesiology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-2999(94)00780-B","article-title":"Scratching behavior induced by pruritogenic but not algesiogenic agents in mice","volume":"275","author":"Kuraishi","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-0102(99)00070-X","article-title":"Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice","volume":"35","author":"Yamaguchi","year":"1999","journal-title":"Neurosci. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejphar.2004.09.010","article-title":"Kappa opioid agonists suppress chloroquine-induced scratching in mice","volume":"502","author":"Inan","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejphar.2005.11.012","article-title":"Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2","volume":"530","author":"Shimada","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neuroscience.2015.09.055","article-title":"Phoenixin: A candidate pruritogen in the mouse","volume":"310","author":"Cowan","year":"2015","journal-title":"Neuroscience"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000053599","article-title":"NC\/Nga mice: A mouse model for atopic dermatitis","volume":"120","author":"Suto","year":"1999","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1097\/j.pain.0000000000000674","article-title":"Mouse model of imiquimod-induced psoriatic itch","volume":"157","author":"Sakai","year":"2016","journal-title":"Pain"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1254\/jjp.88.285","article-title":"Itch-associated response induced by experimental dry skin in mice","volume":"88","author":"Miyamoto","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","article-title":"Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A","volume":"26","author":"Aoki","year":"2005","journal-title":"Neurotoxicology"},{"key":"ref_169","first-page":"201","article-title":"Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain","volume":"46","year":"2005","journal-title":"Croat. Med. J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.2174\/0929867327666200806105024","article-title":"The Mechanisms of Action of Botulinum Toxin Type A in Nociceptive and Neuropathic Pathways in Cancer Pain","volume":"28","author":"Salcedo","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Ramachandran, R., Marino, M.J., Paul, S., Wang, Z., Mascarenhas, N.L., Pellett, S., Johnson, E.A., DiNardo, A., and Yaksh, T.L. (2018). A Study and Review of Effects of Botulinum Toxins on Mast Cell Dependent and Independent Pruritus. Toxins, 10.","DOI":"10.3390\/toxins10040134"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nbd.2012.07.010","article-title":"Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A","volume":"48","author":"Shimizu","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J. Urol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1073\/pnas.71.2.408","article-title":"Calcium-induced extrusion of secretory granules (exocytosis) in mast cells exposed to 48\/80 or the ionophores A-23187 and X-537A","volume":"71","author":"Cochrane","year":"1974","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1083\/jcb.88.1.160","article-title":"Structural evidence that botulinum toxin blocks neuromuscular transmission by impairing the calcium influx that normally accompanies nerve depolarization","volume":"88","author":"Hirokawa","year":"1981","journal-title":"J. Cell Biol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/WNR.0000000000000779","article-title":"Long-term anti-itch effect of botulinum neurotoxin A is associated with downregulation of TRPV1 and TRPA1 in the dorsal root ganglia in mice","volume":"28","author":"Cao","year":"2017","journal-title":"Neuroreport"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdermsci.2020.11.003","article-title":"Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system","volume":"101","author":"Amalia","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/T(H) 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Jabeen, M., Boisgard, A.S., Danoy, A., El Kholti, N., Salvi, J.P., Boulieu, R., Fromy, B., Verrier, B., and Lamrayah, M. (2020). Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090789"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/jid.2011.60","article-title":"Cutaneous Denervation of Psoriasiform Mouse Skin Improves Acanthosis and Inflammation in a Sensory Neuropeptide-Dependent Manner","volume":"131","author":"Ostrowski","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1365-2133.2006.07518.x","article-title":"The role of neuropeptides in psoriasis","volume":"155","author":"Saraceno","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"696784","DOI":"10.3389\/fimmu.2021.696784","article-title":"Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis","volume":"12","author":"Meng","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","article-title":"Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential","volume":"29","author":"Meng","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"21226","DOI":"10.1038\/srep21226","article-title":"TNF\u03b1 induces co-trafficking of TRPV1\/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18\u20131\/syntaxin1\/SNAP-25 mediated fusion","volume":"6","author":"Meng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e71689","DOI":"10.7554\/eLife.71689","article-title":"BNP facilitates NMB-encoded histaminergic itch via NPRC-NMBR crosstalk","volume":"10","author":"Meng","year":"2021","journal-title":"Elife"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nsmb.1626","article-title":"Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F","volume":"16","author":"Agarwal","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Rojewska, E., Piotrowska, A., Popiolek-Barczyk, K., and Mika, J. (2018). Botulinum Toxin Type A\u2014A Modulator of Spinal Neuron-Glia Interactions under Neuropathic Pain Conditions. Toxins, 10.","DOI":"10.3390\/toxins10040145"},{"key":"ref_188","first-page":"723","article-title":"Glial Cells are Involved in Itch Processing","volume":"96","author":"Andersen","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/CCID.S189000","article-title":"Inverse Psoriasis: From Diagnosis to Current Treatment Options","volume":"12","author":"Micali","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Weise, D., Weise, C.M., and Naumann, M. (2019). Central Effects of Botulinum Neurotoxin\u2014Evidence from Human Studies. Toxins, 11.","DOI":"10.3390\/toxins11010021"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.toxicon.2017.10.027","article-title":"Direct central nervous system effects of botulinum neurotoxin","volume":"147","author":"Caleo","year":"2018","journal-title":"Toxicon"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Luvisetto, S. (2021). Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy. Toxins, 13.","DOI":"10.3390\/toxins13110751"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"641746","DOI":"10.3389\/fmed.2021.641746","article-title":"Neuropathic Itch: Routes to Clinical Diagnosis","volume":"8","author":"Pereira","year":"2021","journal-title":"Front. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/physrev.00045.2019","article-title":"Neuropathic Pain: From Mechanisms to Treatment","volume":"101","author":"Finnerup","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"853","DOI":"10.5114\/ada.2019.82795","article-title":"The whole truth about botulinum toxin\u2014A review","volume":"37","author":"Witmanowski","year":"2020","journal-title":"Allergol. Post\u0119py Dermatol. Alergol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"adv00025","DOI":"10.2340\/00015555-3345","article-title":"Non-dermatological Challenges of Chronic Itch","volume":"100","author":"Kremer","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaci.2019.04.005","article-title":"Itching as a systemic disease","volume":"144","author":"Hashimoto","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Winayanuwattikun, W., and Vachiramon, V. (2022). Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article. Toxins, 14.","DOI":"10.3390\/toxins14060406"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bjd.16080","article-title":"The non-neuronal and nonmuscular effects of botulinum toxin: An opportunity for a deadly molecule to treat disease in the skin and beyond","volume":"178","author":"Grando","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00702-022-02494-5","article-title":"Botulinum toxin therapy: Past, present and future developments","volume":"129","author":"Dressler","year":"2022","journal-title":"J. Neural Transm."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/10\/701\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:52:41Z","timestamp":1760143961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/10\/701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":201,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["toxins14100701"],"URL":"https:\/\/doi.org\/10.3390\/toxins14100701","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}